AI Article Synopsis
- - The Baveno VI Consensus established criteria (liver stiffness <20 kPa and platelet count >150 x 10 cells/L) to identify patients with compensated advanced chronic liver diseases (cACLD) who are unlikely to need treatment for varices, allowing them to skip screening endoscopy.
- - A meta-analysis reviewed 13 studies with 4,464 patients to evaluate the safety and efficacy of these criteria, finding that the missed rate of varices needing treatment was just 0.3%, while the rate of spared endoscopies was 32.8%.
- - For cCLD patients (with 27 studies involving 7,534 patients), the missed rate was 0.2% and the
Article Abstract
The Baveno VI Consensus Workshop defined criteria (liver stiffness measured by transient elastography <20 kPa and platelet count >150 × 10 cells/L) to identify those patients with compensated advanced chronic liver diseases (cACLD) who are unlikely to have varices needing treatment (VNTs) and can safely avoid variceal screening endoscopy. This meta-analysis aimed to quantify the safety and efficacy of these criteria in suspected cACLD with liver stiffness >10 kPa and in compensated chronic liver diseases (cCLD) irrespective of liver stiffness. A systematic search was conducted in nine databases for studies discussed cACLD or cCLD and tested Baveno criteria against variceal screening endoscopy. The main safety and efficacy endpoints were missed VNT rate and spared endoscopy rate (SER), respectively; calculated with the random effect model. Pooled sensitivity, specificity, and area under the curve (AUC) were calculated with the hierarchical summary receiver operating characteristic model. For all outcome measures, 95% confidence intervals were computed. Heterogeneity was tested with -statistics. The search yielded 13 studies including 4,464 patients which reported on suspected cACLD. Pooled missed VNT rate was 0.3% (0.1-0.6%; = 45.5%), pooled SER was 32.8% (24.8-41.4%; = 97.0%). Sensitivity, specificity, and AUC of Baveno criteria were 97% (95-98%), 41% (27-57%), and 96% (94-97%), respectively. In the subgroups of cACLD from hepatitis C and B viruses, non-alcoholic fatty liver disease/steatohepatitis, or alcohol, missed VNT rates were 0.0% (0.0-0.3%), 1.2% (0.4-2.2%), 0.0% (0.0-1.3%), or 0.0% (0.0-0.4%), while SERs were 24.2% (20.5-28.1%), 24.9% (21.7-28.4%), 38.6% (10.9-70.8%), or 27.0% (16.9-38.4%), respectively. If we expanded the study population to cCLD, 27 studies included 7,534 patients. Missed VNT rate was 0.2% (0.1-0.5%; = 39.8%) with a SER of 30.5% (25.2-36.2%; = 96.1%) while Se, Sp, and AUC were 97% (93-99%), 35% (27-44%), and 80% (77-84%), respectively. The application of Baveno criteria significantly reduces the number of unnecessary variceal screening endoscopies while being safe: cACLD patients with liver stiffness <20 kPa and platelet count > 150 × 10 cells/L carry a very low chance (i.e., 0.3%) of having VNTs. The criteria preserve low missed VNT rate with lower diagnostic performance among cCLD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711320 | PMC |
| http://dx.doi.org/10.3389/fphys.2019.01028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Performance of Baveno VII criteria for the screening of varices needing treatment in patients with biliary atresia.
J Pediatr Gastroenterol Nutr
August 2024
Departments of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Objective: Biliary atresia (BA) is the leading cause of liver cirrhosis and chronic liver insufficiency in children in the world. Gastroesophageal varices bleeding is an ominous complication of cirrhosis in BA patients and is associated with high morbidity and mortality. In this study, we aimed to investigate the utility of noninvasive Baveno VI and Baveno VII criteria for the screening of varices need treatment (VNT) and the need for liver transplantation in BA patients.
View Article and Find Full Text PDFGene-Gene Interaction Between Factor- and Genes in Cerebral Venous Thrombosis: The BEAST Study.
Neurology
June 2024
From the Institute of Cardiovascular Research Royal Holloway (G.K.-D., P.S.), University of London (ICR2UL), United Kingdom; Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico (I.M., S.M.P., M.A., P.B., E.P.), A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Moncucco Hospital Group (I.M., E.G.), Lugano, Switzerland; Atherosclerosis and Thrombosis Unit (E.G., G.F., D.C.), I.R.C.C.S. Fondazione "Casa Sollievo della Sofferenza", S. Giovanni Rotondo; Medical and Surgical Department (E.G.), University of Foggia, Italy; Department of Obstetrics (E.G.), Gynaecology and Perinatal Medicine, First Sechenov University, Moscow, Russia; Neurology (S.H., J.P., E.H., T.T.), Helsinki University Hospital and University of Helsinki, Finland; Department of Clinical Neuroscience (E.L., K.J., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Department of Neurology (E.L., K.J., T.T.), Sahlgrenska University Hospital, Gothenburg, Sweden; Medical Genetics (M. Margaglione, R.S.), Department of Clinical and Experimental Medicine, University of Foggia, Italy; Normandy University (V.L.C.D.), UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit and INSERM CIC-CRB 1404; Department of Neurology (A.B.T.), Rouen University Hospital, France; Neurology Unit (M.Z.), Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia; Department of Clinical and Experimental Medicine (M. Mancuso), Neurological Institute, University of Pisa, Italy; UMC Utrecht Brain Center (Y.M.R.), Department of Neurology and Neurosurgery, University Medical Center Utrecht, the Netherlands; Department of Neurology (B.B.W.), University of Virginia, Charlottesville, VA; Department of Neurology (J.J.M., A.T.), University of Utah, Salt Lake City; Department of Neurology (S.Z., M.C.B., J.M.C.), Amsterdam University Medical Centers, location AMC, Amsterdam Neuroscience, University of Amsterdam, the Netherlands; Department of Neurosciences (R.L.), Experimental Neurology, KU Leuven-University of Leuven; VIB Center for Brain & Disease Research; Department of Neurology, University Hospitals Leuven, Belgium; Department of Pathophysiology and Transplantation (E.P.), Università degli Studi di Milano, Milan; Department of Clinical and Experimental Sciences (P. Costa), Neurology Clinic; Division of Biology and Genetics (M.C.), Department of Molecular and Translational Medicine, University of Brescia, Italy; Stroke Center (D.A.D.S.), Centro Hospitalar Universitário Lisboa Central; CEEM and Institute of Anatomy (D.A.D.S.), Faculdade de Medicina; Instituto de Medicina Molecular João Lobo Antunes (D.A.D.S., J.M.F.), Universidade de Lisboa; Department of Neurosciences (S.G.R., P. Canhao), Hospital of Santa Maria, University of Lisbon, Portugal; Stroke Clinic (A.A.), National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Mexico City; Department of Neurology (K.S.), University of Athens School of Medicine, Eginition Hospital, Athens, Greece; McMaster University (A.H., R.D., G.P.), Pathology and Molecular Medicine, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine and Surgery (A.P.), University of Parma, Stroke Care Program, Department of Emergency, Parma University Hospital, Italy; Stroke Division (V.N.T.), Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia; and Department of Clinical Neuroscience (P.S.), Imperial College Healthcare NHS Trust, London, United Kingdom.
Article Synopsis
- Gene-gene interactions are believed to play a significant role in the development of multifactorial diseases like cerebral venous thrombosis (CVT), highlighting potential causes of unexplained heritability.
- A study involving 882 CVT patients and 1,205 control participants found that specific gene variants significantly increased the likelihood of developing CVT, particularly when individuals had certain blood types.
- The research concluded that the interactions between specific genes could raise the risk of CVT by as much as 14 times, underscoring the importance of understanding these genetic factors in disease etiology.
Spleen Stiffness-Based Algorithms Are Superior to Baveno VI Criteria to Rule Out Varices Needing Treatment in Patients With Advanced Chronic Liver Disease.
Am J Gastroenterol
August 2024
Department of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium.
Introduction: The Baveno VI criteria have set the stage for noninvasive assessment of compensated advanced chronic liver disease (ACLD). The algorithm combining liver stiffness measurement (LSM, <20 kPa) and platelet count (>150,000/μL) safely avoids screening endoscopy for varices needing treatment (VNT) but identifies only a relatively low number of patients. We aimed to evaluate the value of spleen stiffness measurement (SSM) using spleen-dedicated elastography in ruling out VNT.
View Article and Find Full Text PDFA new criterion including the aspartate aminotransferase-to-platelet ratio index and liver and spleen stiffness to rule out varices needing treatment in children with biliary atresia: Modification of the Baveno VII criteria.
Hepatol Res
April 2024
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Article Synopsis
- The study investigates the risk of needing treatment for varices (enlarged veins) in children with biliary atresia (BA), a serious liver condition that can occur in newborns or infants.
- Using advanced imaging techniques, researchers assessed liver and spleen stiffness in 53 BA patients to determine the likelihood of requiring endoscopic treatments for varices.
- A new combined diagnostic method involving liver stiffness, spleen stiffness, and a lab test drastically lowered the chance of missing varices needing treatment to just 5%, improving patient care and monitoring.
Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma.
Cancers (Basel)
April 2023
State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Hong Kong Cancer Institute, Hong Kong SAR, China.
The Baveno VII criteria are used in patients with liver cirrhosis to predict high-risk varices in patients with liver cirrhosis. Yet its use in patients with advanced hepatocellular carcinoma (HCC) has not been validated. HCC alone is accompanied with a higher variceal bleeding risk due to its association with liver cirrhosis and portal vein thrombosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!